Study Title
A Phase I/II Study of Nivolumab in Combination with 5-azacytidine in pediatric patients with relapsed/refractory acute myeloid leukemia
Protocol ID
T2016-002
Disease (Sub Disease)
Leukaemia (AML)
Diagnosis Stage
Relapsed/ refractory
Sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Collaborators
Bristol-Myers Squibb
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
1 Year to 30 Years
International registry ID's
NCT03825367
| Study Title | A Phase I/II Study of Nivolumab in Combination with 5-azacytidine in pediatric patients with relapsed/refractory acute myeloid leukemia |
|---|---|
| Protocol ID | T2016-002 |
| Disease (Sub Disease) | Leukaemia (AML) |
| Diagnosis Stage | Relapsed/ refractory |
| Sponsor | Therapeutic Advances in Childhood Leukemia Consortium |
| Collaborators | Bristol-Myers Squibb |
| Links | https://clinicaltrials.gov/ct2/show/NCT03825367 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 22/11/2021 |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | 1 Year to 30 Years |
| International registry ID's | NCT03825367 |